BIOAVAILABILITY AND DISSOLUTION ENHANCEMENT OF GLYBURIDE NANOSUSPENSION

  • PRADEEP KUMAR M Department of Pharmaceutical Sciences, Jawaharlal Nehru Technological University, Ananthapuram, Andhra Pradesh, India.

Abstract

Objective: The main objective was to develop nanosuspension of glyburide (GLY) by quasi emulsification solvent diffusion method and to enhance dissolution and bioavailability characteristics of the drug GLY, an antidiabetic drug which belongs to Biopharmaceutical Classification System-II category.


Materials and Methods: In this work, nanoparticles were prepared using polyvinyl alcohol, hydroxypropyl methyl cellulose, and Eudragit RL100. Twelve formulations of GLY (GLY-1–GLY-12) were formulated using the excipients at various compositions. Drug and excipient compatibility studies were conducted using Fourier transform infrared and differential scanning calorimeter. The prepared nanosuspension was analyzed using scanning electron microscopy for surface of the particle analysis, melting point, solubility, particle charge zeta (mv), percentage drug entrapment efficiency (%), and in vitro drug release. The optimized formulations of nanosuspension were further studied for in vivo pharmacokinetic evaluation. Reverse-phase high-performance liquid chromatography method was developed, validated, and used for the study of these formulations in rat plasma.


Results: From these studies, it was confirmed that drugs and excipients chosen were compatible with each other. GLY-8 was the best formulation with a particle size of 85–96 nm with 168.7°C melting point, freely soluble in phosphate buffer pH 7.4, 93.53% drug entrapment, and 90.26±1 mV of zeta potential. This formulation shows percentage drug release of 99.85% in 24 h. In vivo pharmacokinetic study for optimized formulation (GLY -8) suggested that there was no reaction with the rat plasma. From the results, it was shown that Cmax and Tmax were found to be 0.604±0.03 μg/ml and 2±1.01 h, respectively. The values of t1/2 (h), area under the curve (AUC) (0-t), and AUC (0-∞) were found to be 10.04 h, 2.562±0.41 μg.h/ml, and 2.147±0.45 μg.h/ml, respectively.


Conclusion: Based on the results obtained, oral administration of nanosuspension could not only provide the better absorption of poorly water soluble drugs but may also reduce toxicity and provide a new tool in drug delivery system.

Keywords: Glyburide, Scanning electron microscopy studies, In vitro drug release, In vivo pharmacokinetic evaluation, Dissolution and bioavailability enhancement.

References

1. Bergstroem CA, Wassvik CM, Johansson K, Hubatsch I. Poorly soluble marketed drugs display solvation limited solubility. J Med Chem 2007;50:5858-62.
2. Wei H, Dalton C, Di Maso M, Kanfer I, Löbenberg R. Physicochemical characterization of five glyburide powders: A BCS based approach to predict oral absorption. Eur J Pharm Biopharm 2008;69:1046-56.
3. Kohli S, Pal A, Jain S. Preparation, characterization and evaluation of poly (lactide–co–glycolide) microspheres for the controlled release of zidovudine. Int J Pharm Pharm Sci 2017;9:70-7.
4. Reza MI, Goel D, Gupta RK, Warsi MH. Formulation of ketoconazole loaded nano dispersive gel using swollen micelles technique and its in vitro characterization. Int J Pharm Pharm Sci 2017;10:162-6.
5. Atar SA, Soniwala M. Formulation and evaluation of pectin-calcium chloride beads of azathioprine for colon targeted drug delivery system. Int J Pharm Pharm Sci 2018;10:172-7.
6. Powar PV. Development status in the meadow of nanostructure magnetic drug delivery system and its promising applications. Int J Pharm Pharm Sci 2017;9:10-7.
7. Kunal S, Ravindra B. UV spectrophotometric method for the estimation of azilsartan medoxomil in bulk and pharmaceutical formulations. World J Pharm Res 2015;4:1667-72.
8. Gandhi S, Mittal P, Pahade A, Rege S. Development and validation of stability indicating HPTLC method for estimation of azilsartan medoxomil. Pharm Sci Monit 2015;6:224-32.
9. Winarti L, Sari LO, Nugroho AE. Naringenin-loaded chitosan nanoparticles formulation and its in vitro evaluation against t47d breast cancer cell line. Indones J Pharm 2015;26:145-57.
10. Pignatello R, Bucolo C, Ferrara P, Maltese A, Puleo A, Puglisi G, et al. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci 2002;16:53-61.
11. Prakash S, Vidyadhara S, Sasidhar RL, Abhijit D, Akhilesh D. Development and characterization of ritonavir nanosuspension for oral use. Pharm Lett 2013;5:48-55.
12. Dong Y, Ng WK, Hu J, Shen S, Tan RB. A continuous and highly effective static mixing process for antisolvent precipitation of nanoparticles of poorly water-soluble drugs. Int J Pharm 2010;386:256 61.
13. Huong DT, Takahashi Y, Ide T. Activity and mRNA levels of enzymes involved in hepatic fatty acid oxidation in mice fed citrus flavonoids. Nutrition 2006;22:546-52.
14. Rajalakshmi R, Venkataramudu T, Kumar R, Divya K, Kiranmayi M. Design and characterization of valsartan nanosuspension. Int J Pharmacother 2012;2:70-81.
15. Kroyer G. The antioxidant activity of citrus fruit peels. Z Ernahrungswiss 1986;25:63-9.
16. Sahu BP, Das MK. Nanosuspension for enhancement of oral bioavailability of felodipine. Appl Nanosci 2013;4:1-9.
Statistics
40 Views | 19 Downloads
How to Cite
PRADEEP KUMAR M. “BIOAVAILABILITY AND DISSOLUTION ENHANCEMENT OF GLYBURIDE NANOSUSPENSION”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 12, no. 4, Feb. 2019, pp. 111-8, https://innovareacademics.in/journals/index.php/ajpcr/article/view/31657.
Section
Original Article(s)